Congenital LQTS and Drugs to Avoid List

 

There are over 220 medicines on the Drugs to Avoid (DTA) list for patients with Congenital LQTS (CLQTS).  Avoidance may not always be possible because many patients have conditions that require treatment with these drugs and safe alternatives are not available.  Because there are over 12 different types of CLQTS, some patients may be safely treated with some of the drugs on the DTA list.  Determining which patients can be prescribed these medicines requires special medical expertise and often involves close monitoring of the QT interval.  The following information is provided to help patients, family members and healthcare providers to make these decisions and interpret the different categories of drugs on the DTA list.

 

 

Known_V2.png  Known Risk:  These drugs should only rarely, if ever, be given to patients with CLQTS because the danger is clear.  However, when no alternative safe drug is available and the illness is severe, some patients with CLQTS may be treated by physicians with expertise in the treatment of arrhythmias.

 

 

Possible_V2.png  Possible Risk:  These drugs have been found to increase QT intervals in some patients and for that reason could theoretically be dangerous in CLQTS.  However, if the drugs are medically necessary, they may be prescribed by medical specialists for patients with CLQTS.

 

 

Conditional_V2.png  Conditional Risk:  Most of these can be prescribed safely for many patients with cLQTS because the drug’s risk is confined to certain conditions, e.g. overdose, excessive duration of treatment, use with diuretics or drugs that block their elimination, or patients with other risk factors.

 

 

drugs_to_avoid.png    Special Risk:  These drugs have a theoretical risk of causing arrhythmias in some CLQTS patients because they have adrenaline-like effects.  Many of these medicines are necessary for treatment of asthma, ADHD or nasal congestion.  Physicians with expertise in the treatment of arrhythmias may prescribe these medicines to carefully selected patients with CLQTS.